WeVote
Log In

Bill

RB

Bill

S 3388

Allows pharmacists to transfer Schedule II attention-deficit/hyperactivity disorder prescriptions.

2024-2025 Regular Session Introduced by Rosy Bagolie and 11 co-sponsors

New Jersey pharmacists gain authority to transfer Schedule II ADHD prescriptions between pharmacies without new physician prescriptions, improving patient medication access and continuity.

Approved P.L.2025, c.45.
#pharmaceutic
0
WeVote Research Nonpartisan
Bill Summary · S 3388

Legislative bill overview

S 3388 permits New Jersey pharmacists to transfer Schedule II ADHD prescriptions between patients' pharmacies without requiring patients to obtain a new prescription from their physician. The bill allows pharmacists to facilitate prescription transfers for controlled substances specifically used to treat attention-deficit/hyperactivity disorder, streamlining the refill process.

Why is this important

Many ADHD patients face delays and access barriers when their preferred pharmacy doesn't have their prescription in stock, forcing them to either wait or return to their doctor for a new prescription. This bill reduces administrative friction and improves medication continuity for patients with a chronic condition requiring ongoing treatment. It reflects growing recognition that pharmacists can safely manage certain prescription logistics under appropriate controls.

Potential points of contention

  • Controlled substance safeguards: Schedule II drugs have strict regulations due to abuse potential; critics may worry that expanded pharmacist authority could weaken oversight or create loopholes, though the bill appears limited to established prescriptions
  • Prescriber autonomy: Some physicians argue that prescription transfer authority should remain with doctors to maintain direct control over patient medication management and compliance monitoring
  • Implementation clarity: The bill's specific operational requirements—verification procedures, documentation standards, and liability allocation between pharmacies—may need clarification to ensure consistent safe practice across different pharmacy settings

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.